{"id":"socazolimab-cisplatin-carboplatin-paclitaxel-bevacizumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Socazolimab works by binding to PD-1 and blocking its interaction with PD-L1, thereby enhancing T-cell activation and proliferation. Bevacizumab inhibits angiogenesis by binding to VEGF. Paclitaxel stabilizes microtubules, preventing cell division, while cisplatin and carboplatin form platinum-DNA adducts, interfering with DNA replication and transcription.","oneSentence":"Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:04.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive"},{"name":"Other cancers with PD-L1 expression"}]},"trialDetails":[{"nctId":"NCT06459687","phase":"PHASE3","title":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Lee's Pharmaceutical Limited","startDate":"2024-11-28","conditions":"Cervical Cancer","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","genericName":"Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Socazolimab is a PD-1 inhibitor monoclonal antibody, while Bevacizumab is a VEGF inhibitor monoclonal antibody. Paclitaxel is a microtubule inhibitor, and cisplatin/carboplatin are platinum-based DNA crosslinking agents. Used for Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive, Other cancers with PD-L1 expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}